menu
    • menu
    [{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Deferiprone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Global Rare Diseases \/ Chiesi Global Rare Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Chiesi Global Rare Diseases"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa-iwxj","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Global Rare Diseases \/ Chiesi Global Rare Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Chiesi Global Rare Diseases"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Metreleptin","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Birch Triterpenes","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tanimilast","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Chiesi Global Rare Diseases

    Menu

    Chiesi Global Rare Diseases

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tanimilast

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chiesi Presents Data Showcasing Depth of Respiratory Leadership at the ATS 2024 Conference

                            Details : CHF6001 (tanimilast) is an inhaled phosphodiesterase-4 inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of COPD and asthma.

                            Brand Name : CHF6001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 16, 2024

                            Lead Product(s) : Tanimilast

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metreleptin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chiesi Announces Health Canada Approval of MYALEPTA™ for Patients with Lipodystrophy

                            Details : Myalepta (metreleptin) is a USFDA approved leptin receptor activator, which is now approved by Health Canada for the treatment of congenital or acquired generalized lipodystrophy.

                            Brand Name : Myalepta

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            February 05, 2024

                            Lead Product(s) : Metreleptin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birch Triterpenes

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) Topical Gel for the Treat...

                            Details : Filsuvez (birch triterpenes) is a topical gel which is approved for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa.

                            Brand Name : Filsuvez

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 19, 2023

                            Lead Product(s) : Birch Triterpenes

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegunigalsidase alfa-iwxj

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Protalix BioTherapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase ...

                            Details : Elfabrio (pegunigalsidase alfa-iwxj) is a PEGylated enzyme replacement therapy (ERT) for the treatment of adult patients with Fabry disease. It is a recombinant human α–Galactosidase–A enzyme expressed in plant-cell culture that is designed to provi...

                            Brand Name : Elfabrio

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 10, 2023

                            Lead Product(s) : Pegunigalsidase alfa-iwxj

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Protalix BioTherapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegunigalsidase alfa

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Protalix BioTherapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102...

                            Details : PRX-102 (pegunigalsidase alfa), EC authorized, is a novel PEGylated, covalently crosslinked form of α-galactosidase-A developed as enzyme replacement therapy for fabry disease, was designed to increase plasma half-life and reduce immunogenicity, thereby...

                            Brand Name : PRX-102

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 05, 2023

                            Lead Product(s) : Pegunigalsidase alfa

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Protalix BioTherapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Chiesi Global Rare Diseases

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deferiprone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chiesi Global Rare Diseases Announces Approval of FERRIPROX™ MR Deferiprone Extended-Release Tablets in Cana...

                            Details : Ferriprox™ (deferiprone) is a chelating agent with an affinity for ferric ion (iron III), being developed for the treatment of patients with transfusional iron overload due to thalassemia syndromes.

                            Brand Name : Ferriprox

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 31, 2023

                            Lead Product(s) : Deferiprone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth